Pharmather Secures Key US Patent for Ketamine in ALS Treatment
PharmaTher Holdings Ltd. has been granted a U.S. patent for using ketamine to treat Amyotrophic Lateral Sclerosis (ALS), bolstering...
Dupixent® Approved for Bullous Pemphigoid Treatment
Regeneron and Sanofi announced FDA approval of Dupixent (dupilumab) for bullous pemphigoid (BP) in adults. This approval is based...
Ajovy’s Effectiveness Reinforced in Real-World Migraine Prevention Study
The final analysis of the two-year PEARL study, presented at the 2025 European Academy of Neurology Congress, demonstrated the...
Enterome Reports Positive Results in Lymphoma Treatment
Enterome presented positive interim Phase 1/2 trial data for its OncoMimics™ immunotherapy, EO2463, in combination with lenalidomide and rituximab...
Dupixent® Approved for Bullous Pemphigoid Treatment
The FDA approved Dupixent (dupilumab) for bullous pemphigoid (BP) in adults. This approval is based on positive results from...
Nerivio® Impact on Migraine Treatment Highlighted in 3 Real-World Studies
Theranica presented three new real-world studies on their Nerivio® REN wearable at the 2025 American Headache Society meeting. The...
Biomea Fusion’s BMF-650 Shows Strong Weight Loss, Appetite Suppression in Preclinical Primate Study
Biomea Fusion announced positive preclinical results for BMF-650, an oral GLP-1 receptor agonist for obesity, in a 28-day study...
Senti-202: FDA Grants Orphan Drug Designation for AML Treatment
Senti Biosciences announced that the FDA granted Orphan Drug Designation to SENTI-202 for relapsed/refractory hematologic malignancies, including acute myeloid...
Axsome to Present Symbravo Data at American Headache Society Meeting
Axsome Therapeutics announced that data from the SYMBRAVO (meloxicam and rizatriptan) clinical program will be presented at the 67th...
Neurona Doses First Patient in NRTX-1001 Cell Therapy Trial
Neurona Therapeutics has dosed the first patient in a Phase 1/2 clinical trial of NRTX-1001, a regenerative cell therapy,...